Rheumatoid arthritis is an autoimmunity leading to considerable impairment of quality of life. N-acetyl glucosamine (GlcNAc) has been described previously as a potent modulator of experimental arthritis in animal models and is used for osteoarthritis treatment in humans, praised for its lack of adverse effects. In this study we present a comprehensive immunological analysis of multivalent GlcNAc-terminated glycoconjugate (GC) application in the treatment of collagen-induced arthritis (CIA) and its clinical outcome. We used immunohistochemistry and FACS to describe conditions on the inflammation site. Systemic and clinical effects were evaluated by FACS, cytotoxicity assay, ELISA, cytometric bead array (CBA), RT-PCR and clinical scoring. We found reduced inflammatory infiltration, NKG2D expression on NK and suppression of T, B and antigen-presenting cells (APC) in the synovia. On the systemic level, GCs prevented the activation of monocyte- and B cell-derived APCs, the rise of TNF-α and IFN-γ levels, and subsequent type II collagen (CII)-specific IgG2a formation. Moreover, we detected an increase of anti-inflammatory IL-4 mRNA in the spleen. Similar to the synovia, the GCs caused a significant reduction of NKG2D-expressing NK cells in the spleen without influencing their lytic function. GCs effectively postponed the onset of arthritic symptoms, reduced their severity and in 18% (GN8P) and 31% (GN4C) of the cases completely prevented their appearance. Our data prove that GlcNAc glycoconjugates prevent the inflammatory response, involving proinflammatory cytokine rise, APC activation and NKG2D expression, leading to the attenuation of clinical symptoms. These results support the glycobiological approach to the treatment of collagen-induced arthritis/rheumatoid arthritis (CIA/RA) as a way of bringing new prospects for more effective therapeutic interventions.

Laboratory of Molecular Biology and Immunology Institute of Microbiology ASCR v v i Prague Czech Republic

Zobrazit více v PubMed

Feldmann M. Pathogenesis of arthritis: recent research progress. Nat Immunol. 2001;2:771–773. PubMed

Ngian GS. Rheumatoid arthritis. Aust Fam Physician. 2010;39:626–628. PubMed

Azuma K, Osaki T, Wakuda T, et al. Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models. Inflammation. 2012;35:1462–1465. PubMed

Alavi A, Axford JS. Sweet and sour: the impact of sugars on disease. Rheumatology (Oxf) 2008;47:760–770. PubMed

Collins ES, Galligan MC, Saldova R, et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxf) 2013;52:1572–1582. PubMed

Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251–256. PubMed

Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol. 2005;43:187–201. PubMed

Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 2007;27:213–218. PubMed

Hua J, Suguro S, Hirano S, Sakamoto K, Nagaoka I. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res. 2005;54:127–132. PubMed

Lindhorst TK. Artificial multivalent sugar ligands to understand and manipulate cabohydrate–protein interactions. Top Curr Chem. 2002;218:201–235.

Hulikova K, Svoboda J, Benson V, Grobarova V, Fiserova A. N-acetyl-D-glucosamine-coated polyamidoamine dendrimer promotes tumor-specific B cell responses via natural killer cell activation. Int Immunopharmacol. 2011;11:955–961. PubMed

Hulikova K, Grobarova V, Krivohlava R, Fiserova A. Antitumor activity of N-acetyl-D-glucosamine-substituted glycoconjugates and combined therapy with keyhole limpet hemocyanin in B16F10 mouse melanoma model. Folia Microbiol (Praha) 2010;55:528–532. PubMed

Hulikova K, Benson V, Svoboda J, Sima P, Fiserova A. N-acetyl-D-glucosamine-coated polyamidoamine dendrimer modulates antibody formation via natural killer cell activation. Int Immunopharmacol. 2009;9:792–799. PubMed

Richter J, Benson V, Grobarova V, et al. CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. Clin Immunol. 2010;136:139–147. PubMed

Benson V, Grobarova V, Richter J, Fiserova A. Glycosylation regulates NK cell-mediated effector function through PI3K pathway. Int Immunol. 2010;22:167–177. PubMed

Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007;2:1269–1275. PubMed

Khachigian LM. Collagen antibody-induced arthritis. Nat Protoc. 2006;1:2512–2516. PubMed

Conigliaro P, Scrivo R, Valesini G, Perricone R. Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev. 2011;10:577–581. PubMed

de Matos CT, Berg L, Michaelsson J, Fellander-Tsai L, Karre K, Soderstrom K. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology. 2007;122:291–301. PubMed PMC

Dalbeth N, Callan MF. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 2002;46:1763–1772. PubMed

Aramaki T, Ida H, Izumi Y, et al. A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol. 2009;19:245–252. PubMed

Lo CK, Lam QL, Sun L, et al. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum. 2008;58:2700–2711. PubMed

Flodstrom-Tullberg M, Bryceson YT, Shi FD, Hoglund P, Ljunggren HG. Natural killer cells in human autoimmunity. Curr Opin Immunol. 2009;21:634–640. PubMed

Kong X, Liu C, Zhang C, et al. The suppressive effects of Saposhnikovia divaricata (Fangfeng) chromone extract on rheumatoid arthritis via inhibition of nuclear factor-kappaB and mitogen activated proteinkinases activation on collagen-induced arthritis model. J Ethnopharmacol. 2013;148:842–850. PubMed

Lindhorst TK, Kieburg C. Glycocoating of oligovalent amines: synthesis of thiourea-bridged cluster glycosides from glycosyl isothiocyanates. Angew Chem Int Ed Engl. 1996;35:1953–1956.

Fiserova A, Kovaru H, Hajduova Z, et al. Neuroimmunomodulation of natural killer (NK) cells by ergot alkaloid derivatives. Physiol Res. 1997;46:119–125. PubMed

Joosten LA, Lubberts E, Helsen MM, et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res. 1999;1:81–91. PubMed PMC

Fujikawa Y, Sabokbar A, Neale S, Athanasou NA. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis. 1996;55:816–822. PubMed PMC

Li J, Hsu HC, Yang P, et al. Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model. Arthritis Rheum. 2012;64:1098–1109. PubMed PMC

Ma L, Rudert WA, Harnaha J, et al. Immunosuppressive effects of glucosamine. J Biol Chem. 2002;277:39343–39349. PubMed

Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA. 2003;100:9452–9457. PubMed PMC

Andersson AK, Sumariwalla PF, McCann FE, et al. Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis. Arthritis Rheum. 2011;63:2617–2629. PubMed

Ogasawara K, Hamerman JA, Ehrlich LR, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 2004;20:757–767. PubMed

Lee IF, Qin H, Priatel JJ, Tan R. Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes. Eur J Immunol. 2008;38:82–89. PubMed

Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright, CD94bright, CD158negative phenotype. Rheumatology (Oxf) 2003;42:870–878. PubMed

Shi FD, Wang HB, Li H, et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol. 2000;1:245–251. PubMed

Nedvetzki S, Sowinski S, Eagle RA, et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood. 2007;109:3776–3785. PubMed

Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA) Clin Exp Immunol. 1998;111:521–526. PubMed PMC

Bossie A, Vitetta ES. IFN-gamma enhances secretion of IgG2a from IgG2a-committed LPS-stimulated murine B cells: implications for the role of IFN-gamma in class switching. Cell Immunol. 1991;135:95–104. PubMed

Williams PJ, Jones RH, Rademacher TW. Correlation between IgG anti-type II collagen levels and arthritic severity in murine arthritis. Autoimmunity. 1998;27:201–207. PubMed

O'Neill SK, Cao Y, Hamel KM, Doodes PD, Hutas G, Finnegan A. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol. 2007;179:5109–5116. PubMed

Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. PubMed

Mussener A, Litton MJ, Lindroos E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA) Clin Exp Immunol. 1997;107:485–493. PubMed PMC

Brennan FM, Maini RN, Feldmann M. TNF alpha – a pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992;31:293–298. PubMed

Feldmann M, Brennan FM, Williams RO, et al. Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog Growth Factor Res. 1992;4:247–255. PubMed

Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307–310. PubMed

Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol. 2000;165:7240–7245. PubMed

Catalan D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12:R68. PubMed PMC

Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158:670–689. PubMed PMC

Myers LK, Tang B, Stuart JM, Kang AH. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol. 2002;102:185–191. PubMed

Kang I, Lee WW, Lee Y. Modulation of collagen-induced arthritis by IL-4 and dexamethasone: the synergistic effect of IL-4 and dexamethasone on the resolution of CIA. Immunopharmacology. 2000;49:317–324. PubMed

Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M. N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis. J Biol Chem. 2011;286:40133–40141. PubMed PMC

Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol. 2005;175:6107–6116. PubMed

Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008;38:921–924. PubMed PMC